Syndax forecasts 2026 R&D and SG&A expenses of $400 million, excluding $50 million in stock option expense

• Syndax Pharmaceuticals forecasts 2026 research and development, selling, general and administrative expenses of $400 million, excluding $50 million in expected stock-option expense.
• Third-quarter revenue rose to $83.3 million from $45.9 million a year earlier.
• Niktimvo collaboration revenue is annualizing at more than $90 million, following $22.6 million in the quarter.
• Revuforj peak annual US net revenue is expected to exceed $2 billion.
• Cash and equivalents totaled $551.1 million as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.